Abstract
Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of the Medical College of Wisconsin Cancer Center, comments on MET and CTLA-4 inhibitors for clear cell renal cell carcinoma, maintenance targeted therapy for patients with metastatic urothelial carcinoma, the landscape of metastatic hormone-sensitive prostate cancer, a consensus definition for platinum ineligibility, and PSMA-positive metastatic castration-resistant prostate cancer.
